Floatz logo

Plerixafor

Noncontiguous Stage II Marginal Zone Lymphoma

Case Comprehensive Cancer CenterSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

106 Active assets in the Noncontiguous Stage II Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Plerixafor is also rated in:

Fanconi anemiaDormant
BB
Indicative ·
70 / 100
View asset →
Hodgkins lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
non-Hodgkin lymphomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →